BioArctic AB (publ) (B9A F) stock market data APIs
€27.1966
0(0%)
as of November 17, 2025
Try our APIs with
free plan!
BioArctic AB (publ) Financial Data Overview
Price chart is built with
Anychart
BioArctic AB (publ) develops biological drugs for patients with central nervous system disorders in Sweden. It engages in the research and development of innovative biological drugs, such as antibodies that address high unmet medical needs. The company's therapeutic areas encompass neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, and other CNS diseases. In addition, it owns a technology platform, which develops a range of therapeutic monoclonal antibodies. Additionally, the company is developing lecanemab, which is in phase 3 clinical trials; Lecanemab that is in back-up phase 3 clinical trials; Exidavnemab, which is in phase 2 clinical trials; Lecanemab, BAN2803, and BAN2802 that are in preclinical trials; and BAN1503, PD-BT2238, ND-BT3814, and GD-BT6822, which are in discovery stage. It has research collaboration agreements with Eisai and AbbVie. The company was formerly known as BioArctic Neuroscience AB and changed its name to BioArctic AB (publ) in 2016. BioArctic AB (publ) was incorporated in 2000 and is based in Stockholm, Sweden.
Prev. Close
27.1966
Open
27.1966
High
27.1966
Low
27.1966
52 wk Range
14.19-32.4
Market Cap
2 505 M
P/E Ratio
26.5631
Shares Outstanding
74 237 K
Revenue
1 916 M
Beta
-0.923
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get BioArctic AB (publ) data using free add-ons & libraries
Get BioArctic AB (publ) Fundamental Data
BioArctic AB (publ) Fundamental data includes:
- Net Revenue: 1 916 M
- EBITDA: 1 301 M
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-13
- EPS/Forecast: -1.06
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
BioArctic AB (publ) News
New
Why BioArctic (OM:BIOA B) Is Up 6.3% After Leqembi Royalties and Novartis Partnership Boost Sales
BioArctic AB reported its third quarter 2025 results, highlighting SEK133.35 million in sales compared to SEK76.63 million a year earlier, alongside a net loss of SEK86.87 million due to increased R&D...
Leqembi® approved for IV maintenance treatment in the United Kingdom
STOCKHOLM, Nov. 13, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Leqembi (lecanemab) has been approved for once every four weeks intravenous...
Interim Report for the period July - September 2025: BioArctic
STOCKHOLM, Nov. 13, 2025 /PRNewswire/ -- Broadening our portfolio with new projects and partnerships Events during the third quarter 2025 New data on lecanemab were presented at the AAIC-congress f...
Invitation to presentation of BioArctic's third quarter report for July - September 2025 on November 13 at 9.30 a.m. CET
STOCKHOLM, Nov. 4, 2025 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) will publish the company's third quarter report for July - September 2025 on Thursday, November 13, 2025, at 08:0...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
